drugset / Trial / NCT04068753
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Timeline
- Start
- 2020-02-26
- Primary completion
- 2026-12
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Niraparib | Small molecule | 200 mg | Oral |